News

Achema with bioeconomy highlights
Enlarge image

BusinessGermany

Achema with bioeconomy highlights

22.06.2012 - Finale at ACHEMA: The world's biggest fair for chemical engineering, biotechnology and environmental protection delivers its final day.

Frankfurt – The fair brings together more than 180,000 participants and 3,770 exhibitors from 56 countries. Hot topics at ACHEMA 2012 are energy and resources. With BiobasedWorld, the organisers have introduced a special industrial biotechnology and biomass processing focus, mirroring how the knowledge-based bioeconomy has started to transform the chemical industry. The bioeconomy is not only a special focus amongst exhibitors, but was also covered by its own "BiobasedWorld" conference.

The importance of the subject was highlighted by a group of 30 science and industry experts from Germany presenting  the "Roadmap Biorefineries". This paper, worked out on behalf of the Federal Government , includes a SWOT analysis on the potential of available biorefinery technologies as well as fields where further research and development efforts are necessary by the year 2030.

Georg Schütte, State Secretary in the Federal Ministry for Education and Research, also introduced three strategic alliances in industrial biotechnology. In these alliances, partners from industry and research from a variety of industry branches work together to foster “biologisation” of industry and to deliver novel biobased products. The alliance "ZeroCarbon Footprint" , coordinated by energy giant RWE Power AG , will have a total volume of €46m, from which the half is financed by public money. It focuses on using carbon-rich waste streams as a basis for novel biotech products. The alliance "Functionalisation of polymers", coordinated by enzyme specialist Evocatal, will see the government und the respective industry partners investing €8m in total. The cosmetics and nutraceuticals alliance "NatLifE", coordinated by BRAIN AG, will have a total volume of €30m.

http://www.european-biotechnology-news.com/news/news/2012-02/achema-with-bioeconomy-highlights.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.26 GBP18.18%
  • EVOCUTIS (UK)0.19 GBP5.56%
  • CERENIS THERAPEUTICS HOLDING SA (F)13.43 EUR5.09%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • 4SC (D)3.17 EUR-8.12%
  • STALLERGENES (F)47.02 EUR-6.07%

TOP

  • KARO BIO (S)41.10 SEK2375.9%
  • BIOTECH PHARMACON (N)16.10 NOK69.5%
  • TIGENIX (B)1.18 EUR66.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-48.6%
  • THROMBOGENICS (B)2.85 EUR-43.0%

TOP

  • KARO BIO (S)41.10 SEK4570.5%
  • ADOCIA (F)87.80 EUR425.4%
  • GALAPAGOS (B)51.42 EUR315.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-82.3%
  • BIOTEST (D)19.82 EUR-77.1%

No liability assumed, Date: 04.09.2015